MucoLife Therapeutics

MucoLife Therapeutics is a biotechnology company focused on developing a novel class of muco-trapping monoclonal antibodies to treat and prevent respiratory and gastrointestinal diseases. Spun out from the University of North Carolina at Chapel Hill, the company leverages technology that engineers the Fc region of antibodies to bind to mucins, effectively trapping pathogens or inflammatory factors within the mucus layer for natural clearance. This approach aims to provide a new therapeutic modality for conditions characterized by problematic mucus, such as cystic fibrosis and COPD, as well as protection against viral infections. The company's platform represents a significant advancement in mucosal immunology and drug delivery.